Physician profile
Steven E Berman
NPI 1720013055
$25,253.95
in general payments reported to CMS, 2019-2025
56 companies · $1,821 in 2025
The $1,821 reported for 2025 was more than what 76% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,525 · 2020: $3,875 · 2021: $2,348 · 2022: $2,394 · 2023: $11K · 2024: $1,447 · 2025: $1,821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,560 · Food and Beverage: $5,552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,560.00 |
| Food and Beverage | $5,551.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $13,293.79 | 2021-2025 | Intellis Adaptivestim, Synchromedii, Inceptiv |
| Abbott Laboratories | $2,316.71 | 2020-2025 | Proclaim, Eterna |
| Medtronic USA, INC. | $1,126.38 | 2019-2020 | |
| Boston Scientific Corporation | $664.39 | 2020-2025 | General - Pain Management, Intracept |
| Tersera Therapeutics LLC | $622.69 | 2019-2025 | Prialt |
| Saluda Medical Americas, INC. | $603.95 | 2023-2025 | Evoke, Evoke Scs |
| Abbvie INC. | $530.23 | 2021-2025 | Ubrelvy, Botox, Qulipta |
| Teva Pharmaceuticals USA, INC. | $528.57 | 2019-2021 | |
| Pfizer INC. | $436.70 | 2019-2025 | |
| Scilex Pharmaceuticals INC. | $410.92 | 2019-2025 | Ztlido |
| Collegium Pharmaceutical, INC. | $388.89 | 2019-2025 | Xtampza |
| Stimwave Technologies Incorporated | $307.76 | 2020-2021 | |
| Nevro Corp. | $299.75 | 2019-2024 | Senza |
| Grt US Holding, INC. | $285.19 | 2021-2022 | |
| Biodelivery Sciences International, INC. | $269.90 | 2019-2021 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Berman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.